John M. Burke, MD, Rocky Mountain Cancer Centers
Articles
MURANO Trial Update in R/R CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Utility of MRD Testing in CLL Management
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Venetoclax Combinations, Safety and Efficacy
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Venetoclax and Obinutuzumab in CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Novel Therapies for Relapsed/Refractory CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Relapsed/Refractory CLL: Treatment Selection
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
BTK inhibitor With vs Without a CD20-Targeted Antibody
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Second-Generation BTK Inhibitors in CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Therapies in the Pipeline for Frontline CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Telemedicine for Patients With CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
BTK Inhibitors in CLL: Ibrutinib
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Current Role for Chemoimmunotherapy in CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Frontline Treatment Options in CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Selecting Frontline Therapy for CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
COVID-19 and CLL Treatment Initiation
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Selecting First-Line Therapy for CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Advances in Frontline Therapy for CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Impact of COVID-19 on Management of CLL
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Initial Work-up for Chronic Lymphocytic Leukemia
William Wierda, MD, PhD, MD Anderson Cancer Center;John Allan, MD, Weill Cornell Medicine;John M. Burke, MD, Rocky Mountain Cancer Centers;Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center;Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center
July 30th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
